Related Experiment Video

Updated: Jun 24, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Failure to metformin and insulin secretagogue monotherapy: an observational cohort study

Laura Pala1, Matteo Monami, Caterina Lamanna

  • 1Section of Endocrinology, Department of Clinical Pathophysiology, University of Florence and Azienda Ospedaliera Careggi, Florence, Italy. l.pala@dfc.unifi.it

Acta Diabetologica
|March 18, 2009
PubMed

Insights

This study found that insulin secretagogues lead to higher treatment failure rates in type 2 diabetes patients compared to metformin. Metformin use was associated with a reduced risk of therapy failure.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Clinical Medicine

Background:

  • Type 2 diabetes management often involves oral hypoglycemic agents.
  • Metformin and insulin secretagogues are common first-line monotherapies.
  • Understanding comparative treatment failure rates is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To assess and compare treatment failure rates between metformin and insulin secretagogue monotherapy in type 2 diabetes.
  • To evaluate the risk of therapy failure in drug-naive patients.
  • To identify factors influencing treatment efficacy in a real-world clinical setting.

Main Methods:

  • Retrospective observational cohort study of 2,020 type 2 diabetic patients.
  • Patients received metformin, insulin secretagogues, or no pharmacological treatment.
  • Follow-up included HbA1c, therapy changes, and adverse events for up to 48 months.
  • Cox regression analysis was used to determine risk factors for treatment failure.

Main Results:

  • Metformin monotherapy was linked to a significantly lower risk of treatment failure.
  • Insulin secretagogue monotherapy was associated with a significantly higher risk of treatment failure.
  • This increased risk with insulin secretagogues persisted even after adjusting for diabetes duration and BMI.

Conclusions:

  • Insulin secretagogues demonstrate a higher failure rate compared to metformin in type 2 diabetes management.
  • The findings suggest a potential detrimental effect of insulin secretagogues rather than solely a beneficial effect of metformin.
  • These results have implications for selecting oral hypoglycemic agents to improve long-term treatment success.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...